國立虎尾科技大學 |

Resistance to Targeted ABC Transporters in Cancer

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Resistance to Targeted ABC Transporters in Cancer/ edited by Thomas Efferth.
其他作者:	Efferth, Thomas.
面頁冊數:	X, 300 p. 60 illus., 21 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer research. -
電子資源:	https://doi.org/10.1007/978-3-319-09801-2
ISBN:	9783319098012

Resistance to Targeted ABC Transporters in Cancer
Resistance to Targeted ABC Transporters in Cancer[electronic resource] /edited by Thomas Efferth. - 1st ed. 2015. - X, 300 p. 60 illus., 21 illus. in color.online resource. - Resistance to Targeted Anti-Cancer Therapeutics,42196-5501 ;. - Resistance to Targeted Anti-Cancer Therapeutics,4.

Role of P-glycoprotein for resistance of tumors to anticancer drugs: From bench to bedside -- Clinical relevance of multidrug-resistance-related proteins (MRPs) for anticancer drug resistance and prognosis -- Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance -- A new strategy of ALA-photodynamic cancer therapy: Inhibition of ABC transporter ABCG2 -- ABC transporters in cancer stem-like cells -- Radiopharmaceuticals for the imaging of ABC-transporter-mediated multidrug resistance in cancer -- Modulation of P-glycoprotein-mediated multidrug resistance by synthetic and phytochemical small molecules, monoclonal antibodies and therapeutic nucleic acids -- ABC transporter modulatory drugs from marine sources: A new approach to overcome drug resistance in cancer -- The role of ABC multidrug transporters in resistance to targeted anti-cancer kinase inhibitors -- Nanotechnology to combat multidrug resistance in cancer -- Drugs affecting epigenetic modifications of ABC transporters.

This volume covers the most current topics relevant to ABC transporters and resistance to novel and established anticancer drugs, prognosis of patients to compounds to modulate multidrug resistance, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors is also discussed. The development of resistance is a major obstacle in cancer chemotherapy since decades. Drug resistance may develop during repeated treatment cycles after initially successful therapy (acquired or secondary resistance). Alternatively, tumors may be resistant from the beginning (inherent or primary resistance). The failure of chemotherapy is a major reason for the fatal outcome of tumor diseases in many patients. Even worse, tumors frequently develop not only resistance to single drugs, but also to many others at the same time. This phenomenon was termed multidrug resistance and decreases the success rates of therapy regimens with combinations of structurally and functionally different drugs. The uncommonly broad spectrum of anticancer agents that are transported by ABC transporters makes these proteins exquisite targets to search for compounds that inhibit their transport function. A huge amount of compounds from many pharmacologically established drug were observed to inhibit ABC transporters and to reverse multidrug resistance—all of these topics and more is explored in this volume.

ISBN: 9783319098012

Standard No.: 10.1007/978-3-319-09801-2doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Resistance to Targeted ABC Transporters in Cancer
LDR:03977nam a22004095i 4500 001 960720
003 DE-He213
005 20200704041650.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319098012 $9 978-3-319-09801-2
024 7 $a 10.1007/978-3-319-09801-2 $2 doi
035 $a 978-3-319-09801-2
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Resistance to Targeted ABC Transporters in Cancer $h [electronic resource] / $c edited by Thomas Efferth.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a X, 300 p. 60 illus., 21 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 4
505 0 $a Role of P-glycoprotein for resistance of tumors to anticancer drugs: From bench to bedside -- Clinical relevance of multidrug-resistance-related proteins (MRPs) for anticancer drug resistance and prognosis -- Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance -- A new strategy of ALA-photodynamic cancer therapy: Inhibition of ABC transporter ABCG2 -- ABC transporters in cancer stem-like cells -- Radiopharmaceuticals for the imaging of ABC-transporter-mediated multidrug resistance in cancer -- Modulation of P-glycoprotein-mediated multidrug resistance by synthetic and phytochemical small molecules, monoclonal antibodies and therapeutic nucleic acids -- ABC transporter modulatory drugs from marine sources: A new approach to overcome drug resistance in cancer -- The role of ABC multidrug transporters in resistance to targeted anti-cancer kinase inhibitors -- Nanotechnology to combat multidrug resistance in cancer -- Drugs affecting epigenetic modifications of ABC transporters.
520 $a This volume covers the most current topics relevant to ABC transporters and resistance to novel and established anticancer drugs, prognosis of patients to compounds to modulate multidrug resistance, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors is also discussed. The development of resistance is a major obstacle in cancer chemotherapy since decades. Drug resistance may develop during repeated treatment cycles after initially successful therapy (acquired or secondary resistance). Alternatively, tumors may be resistant from the beginning (inherent or primary resistance). The failure of chemotherapy is a major reason for the fatal outcome of tumor diseases in many patients. Even worse, tumors frequently develop not only resistance to single drugs, but also to many others at the same time. This phenomenon was termed multidrug resistance and decreases the success rates of therapy regimens with combinations of structurally and functionally different drugs. The uncommonly broad spectrum of anticancer agents that are transported by ABC transporters makes these proteins exquisite targets to search for compounds that inhibit their transport function. A huge amount of compounds from many pharmacologically established drug were observed to inhibit ABC transporters and to reverse multidrug resistance—all of these topics and more is explored in this volume.
650 0 $a Cancer research. $3 1253664
650 0 $a Drug resistance. $3 872072
650 0 $a Molecular biology. $3 583443
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Drug Resistance. $3 782695
650 2 4 $a Molecular Medicine. $3 668353
700 1 $a Efferth, Thomas. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1063063
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319098029
776 0 8 $i Printed edition: $z 9783319098005
776 0 8 $i Printed edition: $z 9783319379968
830 0 $a Resistance to Targeted Anti-Cancer Therapeutics, $x 2196-5501 ; $v 4 $3 1254768
856 4 0 $u https://doi.org/10.1007/978-3-319-09801-2
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)